Estimates Revisions Cogent Biosciences, Inc.
Stocks
COGT
US19240Q2012
Biotechnology & Medical Research
|
Delayed
Nasdaq
00:00:00 05/09/2026 +04
|
5-day change | 1st Jan Change | ||
| 34.76 USD | -0.54% |
|
+0.26% | -2.14% |
| 09-03 | Cogent Biosciences Enters Commercial Supply Agreement With Hovione FarmaCiencia | MT |
| 09-01 | Cogent Biosciences Insider Sold Shares Worth $1,689,493, According to a Recent SEC Filing | MT |
Turnover - Evolution of Analysts' Estimates
Earnings Per Share (EPS) - Evolution of Analysts' Estimates
EBIT - Evolution of Analysts' Estimates
Dividend / Share (DPS) - Evolution of Analysts' Estimates
Cash or Net Debt - Evolution of Analysts' Estimates
| 1m. Revenue rev. | 1y. Revenue rev. | 1y. EPS revision | ||
|---|---|---|---|---|
 | ||||
| ||||
| ||||
| ||||
| ||||
| ||||
| ||||
| ||||
| ||||
| ||||
| Average | ||||
| Weighted average by Cap. |
Turnover
Earnings Per Share (EPS)
EBIT
Dividend / Share (DPS)
Cash or Net Debt
- Stock Market
- Stocks
- COGT Stock
- Consensus Cogent Biosciences, Inc.
- Estimates Revisions
Select your edition
All financial news and data tailored to specific country editions
